EUVIMEDOpdag EUVIMED
Crossref

Low molecular weight fucoidan restores diabetic endothelial glycocalyx by targeting neuraminidase2: A new therapy target in glycocalyx shedding

Zhi Li iD, Ning Wu iD, Jing Wang, Yang Yue, Lihua Geng, Quanbin Zhang iD

British Journal of Pharmacology · 2024-05 · 181 (9) · 1404-1420

DOI: 10.1111/bph.16288 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2024-01-23. Written by Zhi Li and 5 co-authors. Institution: CAS and Shandong Province Key Laboratory of Experimental Marine Biology, Center for Ocean Mega-Science, Institute of Oceanology, Chinese Academy of S…. Major MEDLINE topics: Diabetic Angiopathies, Antineoplastic Agents, Diabetes Mellitus, Polysaccharides. Cited 12 times so far (Crossref); 62 references. Funded by: National Natural Science Foundation of China, Major Scientific & Engineering Projects of Innovation in Shandong Province, Shandong Provincial Natural Science Foundation.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Diabetic vascular complication is a leading cause of disability and mortality in diabetes patients. Low molecular weight fucoidan (LMWF) is a promising drug candidate for vascular complications. Glycocalyx injury predates the occurrence of diabetes vascular complications. Protecting glycocalyx from degradation relieves diabetic vascular complications. LMWF has the potential to protect the diabetes endothelial glycocalyx from shedding. Experimental Approach The protective effect of LMWF on diabetic glycocalyx damage was investigated in db/db mice and Human Umbilical Vein Endothelial Cells (HUVEC) through transmission electron microscopy and WGA labelling. The effect of LMWF on glycocalyx degrading enzymes expression was investigated. Neuraminidase2 (NEU2) overexpression/knockdown was performed in HUVECs to verify the important role of NEU2 in glycocalyx homeostasis. The interaction between NEU2 and LMWF was detected by ELISA and surface plasmon resonance analysis (SPR). Key Results LMWF normalizes blood indexes including insulin, triglyceride, uric acid and reduces diabetes complications adverse events. LMWF alleviates diabetic endothelial glycocalyx damage in db/db mice kidney/aorta and high concentration glucose treated HUVECs. NEU2 is up‐regulated in db/db mice and HUVECs with high concentration glucose. Overexpression/knockdown NEU2 results in glycocalyx shedding in HUVEC. Down‐regulation and interaction of LMWF with NEU2 is a new therapy target in glycocalyx homeostasis. NEU2 was positively correlated with phosphorylated IR‐ β . Conclusion and Implications NEU2 is an effective target for glycocalyx homeostasis and LMWF is a promising drug to alleviate vascular complications in diabetes by protecting endothelial glycocalyx.

Subjects

MeSH terms (MEDLINE)

Diabetic AngiopathiesAntineoplastic AgentsDiabetes MellitusPolysaccharidesMiceAnimalsHumansGlycocalyxMolecular WeightHuman Umbilical Vein Endothelial CellsGlucose

Author keywords

LMWFNEU2diabetic vascular complicationglycocalyxinsulin resistance

Substances

fucoidanAntineoplastic AgentsGlucosePolysaccharides

Authors and institutions

  • CAS and Shandong Province Key Laboratory of Experimental Marine Biology, Center for Ocean Mega-Science, Institute of Oceanology, Chinese Academy of Sciences, Qingdao, China.
  • Research Center for Cardiopulmonary Rehabilitation, University of Health and Rehabilitation Sciences Qingdao Hospital (Qingdao Municipal Hospital), School of Health and Life Sciences, University of Health and Rehabilita…
  • Laboratory for Marine Biology and Biotechnology, National Laboratory for Marine Science and Technology (Qingdao), Qingdao, China.
  • Laboratory for Marine Drugs and Biological Products, National Laboratory for Marine Science and Technology (Qingdao), Qingdao, China.
  • University of Chinese Academy of Sciences, Beijing, China.

ORCID profiles: Zhi Li, Ning Wu, Quanbin Zhang

Funding

  • National Natural Science Foundation of China
  • Major Scientific & Engineering Projects of Innovation in Shandong Province
  • Shandong Provincial Natural Science Foundation
  • Natural Science Foundation of Shandong Province

Cite

APA

Li, Z., Wu, N., Wang, J., Yue, Y., Geng, L., & Zhang, Q. (2024). Low molecular weight fucoidan restores diabetic endothelial glycocalyx by targeting neuraminidase2: A new therapy target in glycocalyx shedding. British Journal of Pharmacology, 181(9), 1404-1420. https://doi.org/10.1111/bph.16288

Vancouver

Li Z, Wu N, Wang J, Yue Y, Geng L, Zhang Q. Low molecular weight fucoidan restores diabetic endothelial glycocalyx by targeting neuraminidase2: A new therapy target in glycocalyx shedding. British Journal of Pharmacology. 2024;181(9):1404-1420. doi:10.1111/bph.16288

BibTeX
@article{Li2024,
  author = {Li, Zhi and Wu, Ning and Wang, Jing and Yue, Yang and Geng, Lihua and Zhang, Quanbin},
  title = {Low molecular weight fucoidan restores diabetic endothelial glycocalyx by targeting neuraminidase2: A new therapy target in glycocalyx shedding},
  journal = {British Journal of Pharmacology},
  year = {2024},
  volume = {181},
  number = {9},
  pages = {1404--1420},
  doi = {10.1111/bph.16288}
}
Start for free →